Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining 308-excimer phototherapy with intramuscular triamcinolone acetonide was effective and well tolerated for treating resistant alopecia totalis, showing a 90% overall response rate in the ten patients studied, with the best results observed in younger patients.

This study found that pigmented vellus and upright regrowing hairs are the only predictive trichoscopic markers of hair regrowth in patients with alopecia totalis and universalis.

This article reviews the need for a reliable and safe method to prevent alopecia areata from progressing to more severe states and reports no new research findings.

This case report described a rare combination of synchronous gallbladder and pancreatic cancers with an unusual initial symptom of complete loss of facial and scalp hair, marking a unique presentation never previously documented for abdominal malignancies in medical literature.

This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.

This study reported that dupilumab, a human monoclonal antibody, induced hair regrowth in patients with alopecia totalis, suggesting its potential as a treatment for this condition.

A woman's complete hair loss condition improved after recovering from COVID-19.

This source reports that platelet-rich plasma may be as effective as intralesional corticosteroids for treating patchy alopecia areata, with potential for earlier and more sustained results, while promising in vitro and animal studies on stem cells highlight the need for more clinical research.

This report describes two cases where topical squaric acid dibutylester application in alopecia totalis patients led to severe pustular lesions, necessitating systemic prednisolone treatment.

In this report, two young patients with corticosteroid-refractory alopecia totalis experienced safety and efficacy from oral tacrolimus.

This retrospective cohort study found that individuals with alopecia totalis or universalis have a higher prevalence of systemic autoimmune diseases, particularly endocrine diseases and inflammatory bowel disease, compared to those with patchy alopecia areata.

Alopecia totalis/universalis involves more intense immune activity and inflammation than patchy alopecia areata.

In this case study, an 11-year-old girl with severe alopecia areata experienced complete hair regrowth and unexpected white-to-black hair repigmentation after switching from baricitinib to ritlecitinib, suggesting that prolonged Janus kinase inhibition may aid both hair and pigment restoration in severe pediatric cases.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

In this case report, a 22-year-old female with recurrent alopecia totalis experienced progressive hair regrowth and scalp health normalization over eight months following individualized homeopathic treatment and nutritional support.

The study presents a case report of a 17-year-old male with rapidly progressive alopecia areata that worsened following emotional stress; the authors reported complete hair regrowth after treatment with individualized homeopathic prescribing, nutritional correction, and lifestyle guidance at Dr Batra’s® Homeopathy Clinic.

In this case study at Dr Batra’s® Homeopathy Clinic, a 15-year-old male with alopecia totalis experienced progressive hair regrowth and emotional well-being improvement over 4-5 months following a classical homeopathic treatment approach, despite previous conventional management.

This retrospective case series reported that pediatric patients with alopecia totalis and subtotalis experienced significant hair regrowth after treatment with the JAK inhibitor upadacitinib, with mild acne as the most common side effect; however, larger studies are needed to establish its efficacy and safety conclusively.

This case study reports on a 13-year-old male with alopecia totalis who experienced successful hair regrowth after being treated with dupilumab, an interleukin-4 and IL-13 antagonist, suggesting its potential utility in managing alopecia areata in pediatric patients with comorbid atopic dermatitis.

In this case study, a 12-year-old boy with alopecia totalis experienced hair regrowth on the side of his scalp treated with a combination of systemic steroids and dithranol, suggesting a potential synergistic effect that may help manage severe alopecia areata with minimal side effects.

This study observed that JAK inhibitors were effective and safe for treating alopecia totalis and universalis, with improved response rates seen most with ritlecitinib and tofacitinib by week 24.

This case report details the significant hair regrowth experienced by a 49-year-old woman with stress-related alopecia totalis after individualized homeopathic treatment, underscoring its potential effectiveness in managing both emotional trauma and hair loss.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

This study found that topical immunotherapy is effective for treating severe alopecia areata, though patient responses can vary, highlighting the importance of individualized treatment approaches and prolonged therapy to optimize outcomes.

In this case study, an 8-year-old boy with alopecia totalis experienced significant hair regrowth after baricitinib treatment, suggesting KRT74 variants may influence immune dysregulation in this condition.

This study reports that a patient with severe, treatment-resistant alopecia areata experienced sustained hair regrowth and emotional improvement over 24 months following individualized homeopathic treatment, suggesting homeopathy may be a viable therapeutic option when conventional treatments fail.

In this case report, a 7-year-old boy with alopecia totalis experienced significant hair regrowth after adding topical tofacitinib and mometasone to his treatment regimen, suggesting potential benefits of topical Janus kinase inhibitors for pediatric patients with this condition.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This case study reported that homeopathic treatment focusing on emotional stress and immune support led to positive outcomes in a patient with alopecia totalis following emotional trauma, suggesting a potential benefit of addressing both physical and emotional factors.

This case report highlights the significance of alopecia totalis and knuckle pad hyperpigmentation as early indicators of azathioprine-induced myelosuppression and pancytopenia.